NEPTUNUS: NEP018 tablets have received the drug clinical trial approval notice

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, NEPTUNUS (000078.SZ) announced that its wholly-owned subsidiary Shenzhen NEPTUNUS Pharmaceutical Technology Research Institute Co., Ltd. (hereinafter referred to as "NEPTUNUS Pharmaceutical Research Institute") recently received the "Drug Clinical Trial Approval Notice" for NEP018 tablets issued by the National Medical Products Administration, agreeing to conduct clinical trials of this product as a monotherapy for advanced malignant solid tumors.

NEP018 tablets are a new type of tumor-targeted small molecule kinase inhibitor independently developed by the NEPTUNUS Pharmaceutical Research Institute, with independent intellectual property rights. Comprehensive preclinical studies have shown that NEP018 tablets have good selective inhibitory activity against the designed targets and exhibit good inhibitory effects on gastrointestinal tumors. The pharmacokinetic tissue distribution is concentrated in the gastrointestinal tract. Given that the current treatment for gastrointestinal tumors primarily relies on chemotherapy drugs supplemented with biological drugs for combination therapy, the development of this project can address the unmet clinical needs for targeted small molecule drugs in gastrointestinal tumors to some extent. The core patent for this project has been granted an invention patent authorization

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.